These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
506 related articles for article (PubMed ID: 9630930)
1. Experimental use and the Orphan Drug Act: a biotechnology conundrum. Koivuniemi PJ Nat Biotechnol; 1996 Apr; 14(4):511-2. PubMed ID: 9630930 [No Abstract] [Full Text] [Related]
2. FDA launches priority vouchers for neglected-disease drugs. Waltz E Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849 [No Abstract] [Full Text] [Related]
3. Promoting, improving and accelerating the drug development and approval processes. Graul AI Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297 [TBL] [Abstract][Full Text] [Related]
4. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA. Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692 [TBL] [Abstract][Full Text] [Related]
5. The Orphan Drug Act: an engine of innovation? At what cost? Rohde DD Food Drug Law J; 2000; 55(1):125-43. PubMed ID: 12322720 [No Abstract] [Full Text] [Related]
6. Incentives for drug development--the curious case of colchicine. Kesselheim AS; Solomon DH N Engl J Med; 2010 Jun; 362(22):2045-7. PubMed ID: 20393164 [No Abstract] [Full Text] [Related]
7. EMEA approves OGS drug rejected by FDA. Mitchell P Nat Biotechnol; 2002 Sep; 20(9):858-9. PubMed ID: 12205490 [No Abstract] [Full Text] [Related]
8. "Creating hope" and other incentives for drug development for children. Connor E; Cure P Sci Transl Med; 2011 Jan; 3(66):66cm1. PubMed ID: 21248312 [TBL] [Abstract][Full Text] [Related]
9. Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act. Arno PS; Bonuck K; Davis M Milbank Q; 1995; 73(2):231-52. PubMed ID: 7776947 [TBL] [Abstract][Full Text] [Related]
10. Prescription for the Orphan Drug Act: the impact of the FDA's 1992 regulations and the latest congressional proposals for reform. Clissold DB Food Drug Law J; 1995; 50(1):125-47. PubMed ID: 10342989 [No Abstract] [Full Text] [Related]
11. The application of the patent laws to the drug approval process. Coggio BD; Cerrito FD Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669 [No Abstract] [Full Text] [Related]
12. Approval times for supplemental indications for recombinant proteins. Gosse ME; Nelson TF Nat Biotechnol; 1997 Feb; 15(2):130-4. PubMed ID: 9035135 [No Abstract] [Full Text] [Related]
13. The Orphan Drug Act Revisited. Thomas S; Caplan A JAMA; 2019 Mar; 321(9):833-834. PubMed ID: 30768155 [No Abstract] [Full Text] [Related]
14. Promoting, improving and accelerating the drug development and approval processes. Graul AI Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899 [TBL] [Abstract][Full Text] [Related]
18. The 1992 biotechnology agenda: a message for candidates Bush and Clinton. Duzan SA Healthspan; 1992 Sep; 9(8):12-5. PubMed ID: 10122052 [No Abstract] [Full Text] [Related]
19. Regulators adopt more orphan drugs. Reardon S Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293 [No Abstract] [Full Text] [Related]
20. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry. Karst KR Am Univ Law Rev; 2000; 49():739-72. PubMed ID: 11067732 [No Abstract] [Full Text] [Related] [Next] [New Search]